未登录

G

Gábor Nagy

Max Planck Institute for Multidisciplinary Sciences

H指数:34

被引数:4,571

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hierarchical multi-timescale structural dynamics of the disordered N-terminal of p53

p53无序N末端的多尺度层级结构动力学

Nature Communications

IF15.7

2026-05-210

OAAI

Transient non-local interactions dominate the dynamics of measles virus NTAIL

瞬时非局部相互作用主导了麻疹病毒NTAIL的动力学。

COMMUNICATIONS CHEMISTRY

IF6.2

2025-10-060

OAAI

Antiviral Potential of Azelastine against Major Respiratory Viruses

氮卓斯汀对主要呼吸道病毒的抗病毒潜力

IF3.5

2023-11-232

OAAI

Anti-Toxin Responses to Natural Enterotoxigenic Escherichia coli (ETEC) Infection in Adults and Children in Bangladesh

IF4.2

2023-10-092

OAAI

Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

IF3.4

2022-02-2117

OAAI

Folding of VemP into translation-arresting secondary structure is driven by the ribosome exit tunnel

NUCLEIC ACIDS RESEARCH

IF13.1

2022-02-1210

OAAI

Implementation of a Bayesian secondary structure estimation method for the SESCA circular dichroism analysis package

COMPUTER PHYSICS COMMUNICATIONS

IF3.4

2021-09-018

OAAI

Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC

IF3.4

2020-11-1623

OAAI

SESCA: Predicting Circular Dichroism Spectra from Protein Molecular Structures

JOURNAL OF CHEMICAL THEORY AND COMPUTATION

IF5.5

2019-08-1166

OAAI

Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing monoclonal IgGs penetrating the epithelial lining fluid

SCIENTIFIC REPORTS

IF3.9

2019-03-2925

OAAI

A New Tool for Complement Research: In vitro Reconstituted Human Classical Complement Pathway

FRONTIERS IN IMMUNOLOGY

IF5.9

2018-12-046

OAAI

Directly Bactericidal Anti-Escherichia coli Antibody

TRENDS IN MICROBIOLOGY

IF14.9

2018-08-012

PREAI

Retained Activity of an O25b-Specific Monoclonal Antibody against an Mcr-1-Producing Escherichia coli Sequence Type 131 Strain

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-07-017

OAAI

Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen

人抗肺炎克雷伯菌LPS O抗原保护性抗体的交叉特异性

NATURE IMMUNOLOGY

IF27.6

2018-05-14102

PREAI

Accurate CD Spectrum Predictions with Sesca: Including Protein Flexibility and Side Chains

BIOPHYSICAL JOURNAL

IF3.1

2018-02-010

OAAI

Multiple Modes of Action of a Monoclonal Antibody against MultidrugResistant Escherichia coli Sequence Type 131-H30

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-11-0118

OAAI

Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3

SCIENTIFIC REPORTS

IF3.9

2017-07-2633

OAAI

Identification of D-Galactan-III As Part of the Lipopolysaccharide of Klebsiella pneumoniae Serotype O1

FRONTIERS IN MICROBIOLOGY

IF4.5

2017-04-2526

OAAI

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258

IF5.4

2017-02-1438

OAAI

Low Efficacy of Antibiotics Against Staphylococcus aureus Airway Colonization in Ventilated Patients

CLINICAL INFECTIOUS DISEASES

IF7.3

2017-02-0417

OAAI